Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics

Jayne, David R. W.; Terrier, Benjamin; Hellmich, Bernhard; Khoury, Farieez; Baylis, Lee; Bentley, Jane H.; Steinfeld, Jonathan; Yancey, Steven W.; Kwon, Namhee; Wechsler, Michael E.; Akuthota, Praveen

dc.contributor.author	Hellmich, Bernhard
dc.date.accessioned	2024-08-14T09:58:33Z
dc.date.available	2024-08-14T09:58:33Z
dc.date.issued	2024
dc.identifier.issn	2312-0541
dc.identifier.uri	http://hdl.handle.net/10900/156800
dc.language.iso	en	en
dc.publisher	Sheffield : European Respiratory Soc Journals Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1183/23120541.00509-2023
dc.subject.ddc	610	de_DE
dc.title	Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics	de_DE
dc.type	Article	de_DE
utue.quellen.id	20240422000000_01101
utue.personen.roh	Jayne, David R. W.
utue.personen.roh	Terrier, Benjamin
utue.personen.roh	Hellmich, Bernhard
utue.personen.roh	Khoury, Farieez
utue.personen.roh	Baylis, Lee
utue.personen.roh	Bentley, Jane H.
utue.personen.roh	Steinfeld, Jonathan
utue.personen.roh	Yancey, Steven W.
utue.personen.roh	Kwon, Namhee
utue.personen.roh	Wechsler, Michael E.
utue.personen.roh	Akuthota, Praveen
dcterms.isPartOf.ZSTitelID	Erj Open Research	de_DE
dcterms.isPartOf.ZS-Issue	1	de_DE
dcterms.isPartOf.ZS-Volume	10	de_DE
utue.fakultaet	04 Medizinische Fakultät